Loading...
Loading...
STRO| Name | Value |
|---|---|
| Revenues | 113.7M |
| Cost of Revenue | 1.7M |
| Gross Profit | 112.0M |
| Operating Expense | 68.8M |
| Operating I/L | 43.2M |
| Other Income/Expense | 3.7M |
| Interest Income | 4.6M |
| Pretax | 46.9M |
| Income Tax Expense | 15.8M |
| Net Income/Loss | 31.1M |
Sutro Biopharma, Inc. is a clinical stage drug discovery and development company specializing in creating protein therapeutics for cancer and autoimmune disorders. The company's primary focus is on its proprietary XpressCF+ platform, which enables the development of protein-based therapeutics. Its product candidates include STRO-001, an antibody-drug conjugate (ADC) for multiple myeloma and non-Hodgkin lymphoma, and STRO-002, an ADC for ovarian and endometrial cancers. Sutro Biopharma also has collaboration and license agreements with Merck and Celgene to develop research programs and bispecific antibodies/ADCs for immuno-oncology.
